HWA
ALNY icon

HCR Wealth Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

HCR Wealth Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$278K Hold
924
– – 0.02% 219
2026
Q1 		$306K Hold
924
– – 0.03% 200
2025
Q4 		$367K Hold
924
– – 0.04% 182
2025
Q3 		$426K Hold
924
– – 0.04% 161
2025
Q2 		$301K Hold
924
– – 0.04% 186
2025
Q1 		$249K Hold
924
– – 0.03% 199
2024
Q4 		$217K Hold
924
– – 0.03% 213
2024
Q3 		$254K Hold
924
– – 0.03% 202
2024
Q2 		$225K Buy
+924
New +$146K 0.03% 208
2023
Q1 		– Sell
-924
Closed -$220K – 176
2022
Q4 		$220K Buy
+924
New +$197K 0.05% 158

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HCR Wealth Advisors's ALNY Position: Q2 2026 in Review

HCR Wealth Advisors held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2026 at 924 shares worth $278K. The position accounts for 0.02% of the portfolio, ranked #219.

HCR Wealth Advisors first reported a position in ALNY in Q4 2022 and has held it in 10 quarters since. The position peaked at $426K in Q3 2025. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • HCR Wealth Advisors held 924 shares of Alnylam Pharmaceuticals worth $278K as of Q2 2026.
  • HCR Wealth Advisors left its Alnylam Pharmaceuticals share count unchanged in Q2 2026.
  • Alnylam Pharmaceuticals made up 0.02% of HCR Wealth Advisors's portfolio in Q2 2026, its #219 holding.
  • HCR Wealth Advisors first reported a position in Alnylam Pharmaceuticals in Q4 2022 and has held it in 10 quarters since.
  • HCR Wealth Advisors's Alnylam Pharmaceuticals position peaked at $426K in Q3 2025.
  • 785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on HCR Wealth Advisors's 13F filing for Q2 2026, filed 13 Jul 2026.